Provided by Tiger Fintech (Singapore) Pte. Ltd.

Y-mAbs Therapeutics, Inc.

4.31
-0.0100-0.23%
Post-market: 4.310.00000.00%17:11 EDT
Volume:157.98K
Turnover:681.63K
Market Cap:195.22M
PE:-6.81
High:4.42
Open:4.30
Low:4.23
Close:4.32
Loading ...

Y-mAbs Therapeutics Inc. Held Annual Stockholders Meeting

Reuters
·
16 Jul

JonesTrading Keeps Their Buy Rating on Y-Mabs Therapeutics (YMAB)

TIPRANKS
·
26 Jun

Oppenheimer Remains a Buy on Y-Mabs Therapeutics (YMAB)

TIPRANKS
·
29 May

Y-mAbs Therapeutics Inc. Unveils Radiopharmaceutical R&D Update, Showcasing Innovative Approaches to Enhance Patient Safety and Treatment Efficacy

Reuters
·
29 May

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)

TIPRANKS
·
29 May

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating

MT Newswires Live
·
28 May

Y-mAbs Therapeutics Inc : Wedbush Cuts Target Price to $18 From $21

THOMSON REUTERS
·
28 May

Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
19 May

Y-mAbs Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
15 May

Truist Securities Adjusts Y-mAbs Therapeutics Price Target to $14 From $18, Maintains Buy Rating

MT Newswires Live
·
14 May

Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Y-mAbs Therapeutics Reports 8% Increase in Q1 2025 Net Product Revenues to $20.9 Million, Net Loss Narrows to $5.2 Million, EPS Improves to ($0.12)

Reuters
·
13 May

BRIEF-Y-mAbs Therapeutics Q1 Net Income USD -5.2 Million Vs. IBES Estimate USD -7.84 Million

Reuters
·
13 May

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

THOMSON REUTERS
·
13 May

Y-mAbs Therapeutics Inc: Reiterates Full Year 2025 Guidance

THOMSON REUTERS
·
13 May

Y-mAbs Therapeutics Q1 Net Income USD -5.2 Million VS. Ibes Estimate USD -7.84 Million

THOMSON REUTERS
·
13 May

Y-mAbs Therapeutics: Cash & Cash Equivalents Anticipated to Be Sufficient to Fund Operations Into 2027

THOMSON REUTERS
·
13 May

Y-mAbs Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
09 May

Y-mAbs Announces Update to National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-Gqgk (Danyelza®)

THOMSON REUTERS
·
07 May

Y-mAbs Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
02 May